10 May

BIO Poised for GUINNESS WORLD RECORDS™ Attempt

On June 4th, thousands of individuals from across the globe will head to Boston – but not for a Red Sox game or a world-famous lobster roll – they’ll be in town for the 2018 BIO International Convention.

It’s not just the packed agenda that will draw nearly 17,000 to attend in Boston this June, it’s BIO One-on-One Partnering™ that helps make Convention the “can’t miss” global event for the biotechnology industry year after year. As BIO continues to celebrate its 25th anniversary over the course of 2018 by looking back at the many important milestones that have been achieved over the years, we look forward to adding another notch to the belt in an official GUINNESS WORLD RECORDS™ attempt while in Boston – the record for the “Largest Business Partnering Meeting” – which is made possible through our industry-leading technology.

BIO One-on-One Partnering™ allows users to efficiently identify potential partners, craft compelling company profiles showcasing their company’s offerings, and communicate with senior business development executives and investors at the touch of a button. In fact, this state-of-the-art platform has proven to be the most efficient way to do business in the biotech and pharma industry without traveling all over the world.

Don’t believe us? Let’s take a look at the numbers:

  • BIO’s One-on-One Partnering™ system will facilitate nearly 1,300 partnering meetings per hour during 2018 Convention;
  • In 2017, more than 41,400 partnering meetings took place – that’s up 16 percent from 2016 – and BIO anticipates that this number will exceed 45,000 in June;
  • 3,500 organizations from nearly 75 countries participated in One-on-One Partnering™ last year; and
  • Since 2015, scheduled partnering meetings at Convention have increased by over 40% and the steady growth is expected to continue at this year’s event.

Be a part of history and join us, June 4-7. Attendees can look forward to a keynote address from Robin Roberts, co-anchor of ABC’s Good Morning America, and dozens of fireside chats and breakout sessions with global biotech and pharma leaders who will discuss everything from innovation to the latest trends and topics being debated on Capitol Hill.

To learn more about the event and available registration packages, please visit convention.bio.org/register.

10 May

With $1.6B Armo Buy, Eli Lilly Is the Latest to Bet Big on Cytokines

Eli Lilly is making a splash in the fast-moving, highly competitive field of cancer immunotherapy. With a $1.6 billion cash deal to acquire Armo BioSciences, the Indianapolis company has placed one of the boldest bets yet that cytokine drugs could be critical in expanding immunotherapy’s reach.

This morning, Lilly (NYSE: LLY) agreed to pay $50 per share, which is a nearly 68 percent premium to Armo’s closing price Wednesday. Redwood City, CA-based Armo (NASDAQ: ARMO) just went public in January at $17 per share. Its lead drug is in late-stage testing for pancreatic cancer.

With the deal, Lilly is… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

10 May

Epygen Biotech to raise Rs 300 Cr to boost Biosimilars in India

After having spent seven years on technology incubation in India and more than a decade of Biotechnology research abroad, Epygen Biotech, one of …

09 May

An Inside Look at CAR-T, Gene Therapy Launches at ‘What’s Hot’ May 16

Getting a new drugmaking technology through clinical development and to market is a major milestone, the culmination of years of scientific work. But the true test of how important that technology is comes afterwards, when the real world gets its hands on it.

This type of story is playing out either right now, or soon will, in biopharma for multiple new forms of cutting edge medicine. Gene therapy, and CAR-T cell therapy, two genetic modification techniques that promise long-lasting results with a single treatment, are in the early days of their commercial launch in the U.S. Another drugmaking method, RNA interference, Read more »

UNDERWRITERS AND PARTNERS

          

          

            

09 May

Global Health Columnist: Anti-GMO is Anti-Science

For decades now, climate change activists have used the scientific evidence of global warming to justify their efforts to increase environmental protections and overall awareness about mankind’s role in heating the earth. And rightfully so. After all, the theories around man’s impact on the environment have been rigorously tested through the scientific method – the gold standard by which scientists hypothesize and test scientific theory.

Through the scientific method we also know that gravity keeps us grounded and the sun does NOT revolve around the earth – principles that are widely accepted and even taught in schools. And through the scientific method, we also know that foods containing genetically modified ingredients (GMOs) are safe.

Therefore, if you’re anti-GMO you’re ignoring the scientific method, and thus discrediting the widely accepted principles that are derived from it. Or, as global health columnist Michael Gerson writes in a piece for the Washington Post, to be anti-GMO is to be anti-science:

In keeping with our era of ideological boycotts, I will no longer be purchasing Kind bars. Or Barilla pasta. Or Triscuit crackers. Or Del Monte diced tomatoes. Or Nutro dog food.

A one-person boycott, of course, is really just a change in your shopping list. But the companies that produce these brands are guilty of crimes against rationality. All advertise on their packaging, in one way or another, that they don’t contain GMOs – genetically modified organisms. Walking down the aisle of my supermarket, I could have picked many other examples. Some food companies seem to be saying that GMO ingredients are not even fit for your dog.

My boycott is rooted in the fact that there is no reputable scientific evidence that direct genetic modification – instead of slower genetic modification through selective breeding – has any health effects of any kind. None. Here is a 2016 analysis of about 1,000 studies by the National Academy of Sciences: “The committee concluded that no differences have been found that implicate a higher risk to human health safety from these [Genetically Engineered] foods than from their non-GE counterparts.” The NAS was joined in this judgment by the Royal Society, the French Academy of Science and the American Medical Association.

So why has Europe essentially banned GMOs? Why do many American food companies treat them like toxins?

Mark Lynas’s new book, “Seeds of Science: Why We Got It So Wrong on GMOs,” tells the story from a unique perspective. Lynas was an early anti-GMO activist in Britain – participating in everything from late-night crop destruction to delivering a pie in the face of Danish statistician Bjorn Lomborg. The logic of Lynas’s conversion is an implicit challenge to both the American right and the left. In an earlier book, “Six Degrees,” Lynas took a deep dive into climate science (winning the Royal Society’s 2008 Science Book Prize in the process). He found the scientific consensus on climate change to be compelling. But he found the evidence for the safety of GMOs to be at least as strong. “I couldn’t deny the scientific consensus on GMOs,” he writes, “while insisting on strict adherence to the one on climate change, and still call myself a science writer.”

It was, he says, “a decisive turning point in my life.” But the public debate on GMOs turned in exactly the opposite direction. Just as scientists were becoming more confident in the safety of GMOs, global anti-GMO activists, led by Greenpeace, were making the issue a hot potato (including a genetically modified insect-resistant potato cultivated in Canada). On the strength of myths (that using genetically modified seeds somehow resulted in suicides among Indian farmers) and deception (tying GMOs to autism or cancer), supermarket chains, food companies and eventually governments were frightened into anti-GMO stances. In the developing world, anti-GMO activists spread rumors that GMO consumption resulted in homosexuality and infertility.

Lynas has carefully avoided writing a screed. He shows considerable patience for the worldview of his former allies: a preference for the small and natural, a fear that agricultural technology results in centralization and increased corporate power.

I have less patience. There is more than a hint of cultural imperialism when Westerners – grown fat on the success of modern farming – lecture subsistence farmers on the benefits of heirloom breeds and organic methods. The greatest need among farmers who spend part of the year hungry is increased productivity. Plant varieties engineered to resist cassava brown streak, banana bacterial wilt or maize lethal necrosis can be a matter of life or death. New, drought-resistant crops will be essential as the climate continues to change. And crops designed to resist insects require the use of far less insecticide – which reduces the risk of pesticide poisoning.

As with the anti-vaccination movement, a contempt for science can have a human cost. The risks are very real when societies become detached from reality.

The anti-GMO movement is best described as a religious belief. Such beliefs have their uses. Theology can determine the values we bring to the world, but it can’t be allowed to dictate our facts. The anti-GMO packaging of Triscuits has the same factual basis as the claim: “No plants or animals produced by evolution were used in the production of this product.” It is the victory of anti-reason. As close as your nearest supermarket.

On left and right, our theologies need to be tethered to empiricism. Our deepest beliefs should help navigate reality, not determine it.

Meanwhile, my dog and I will be shopping in the non-irrationality section.

 

09 May

3 Top Biotech Stocks to Buy in May

The iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) — which is an exchange-traded fund that holds nearly 200 biotech stocks — has …

08 May

Medical Engineering Innovations Eyes $1.2M for Tumor-Zapping Devices

cash, folding money,

Medical Engineering Innovations, a Madison, WI-based developer of medical devices that use radio frequency energy to zap tumors, is raising a funding round led by Serra Ventures, of Champaign, IL. The investment firm says it expects Medical Engineering Innovations (MEI) will have raised $1.2 from Serra Ventures-and, potentially, other investors-when the Series A funding round closes.

MEI says it’s developing surgical devices for the ablation, or elimination, of cancerous tumors. The company’s tools are also aimed at helping healthcare providers perform liver resections-procedures that involve removing diseased liver tissue in cancer patients.

In a news release announcing MEI’s pending… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

08 May

Research Headlines – Challenging gender stereotypes in science

[Source: Research & Innovation] By developing gender-inclusive guidelines and criteria for schools, museums, science centres and industry, an EU-funded project aims to attract more young people, especially girls, to careers in science, technology, engineering and mathematics (STEM).

08 May

Cue Biopharma Appoints Anish Suri Chief Scientific Officer

Anish Suri has been appointed chief scientific officer of preclinical-stage immunotherapy developer Cue Biopharma (NASDAQ: CUE). Suri most recently worked in Belgium at Janssen Immunosciences, where he was senior director. Cambridge, MA-based Cue, which went public at the end of 2017, is developing immunotherapies to treat cancers and autoimmune diseases.

UNDERWRITERS AND PARTNERS

          

          

            

07 May

Only Two Days Left to Nominate for the Xconomy Awards

Last year, the winners of the inaugural Xconomy Awards included a 30-year-old CEO of a young cell therapy startup commercializing his work from MIT (Armon Sharei; Young Innovator); a Dana-Farber oncologist who works closely with breast cancer patients as part of his research (Nikhil Wagle; Patient Partnership); an MIT technology licensing veteran who played a major role in growing Cambridge’s famous Kendall Square (Lita Nelsen; Lifetime Achievement); and two organizations that launched and developed a program to train women for board positions (Biogen and Women in Bio; Commitment to Diversity).

The winners and Read more »

UNDERWRITERS AND PARTNERS